NCT01003769View on ClinicalTrials.gov

Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

5

Participants

Timeline

Start Date

July 9, 2015

Primary Completion Date

December 14, 2018

Study Completion Date

December 14, 2018

Conditions

Recurrent Chronic Lymphocytic Leukemia

Interventions

DRUG

Lenalidomide

Given PO

DRUG

R-(-)-Gossypol Acetic Acid

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (2)

14263

Roswell Park Cancer Institute, Buffalo

32224-9980

Mayo Clinic in Florida, Jacksonville

Sponsors

Lead Sponsor

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER